Stem Cell Therapeutics Corp. has announced that it has received notification of the issuance of two new patents.
The first entitled "Stimulation of Proliferation of Pluripotent Stem Cells through Administration of Pregnancy Associated Compounds" was granted by the United States Patent office; Patent number: 7,994,131.
The second is entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells" and was issued by the Japan Patent Office; Patent number: 4783013.
The first patent relates to the use of the pregnancy hormone human chorionic gonadotropin (hCG) to treat patients presenting with damaged or diseased heart cells.
The second patent adds yet another important territory to SCT's' family of patents relating to the use of granulocyte colony stimulating factor (GM-CSF) to treat white matter disorders by increasing the number of stem cells available to form CNS oligodendrocytes.
White matter disorders include demyelinating diseases that include Multiple Sclerosis, Acute Disseminating Encephalomyelitis, Diffuse Cerebral Sclerosis, and Spinal Cord Injury.
Dr. Allen Davidoff, Chief Scientific Officer of Stem Cell Therapeutics Corp. commented "The rapid succession of granted patents in both neurology and now cardiology is a welcome development for Stem Cell Therapeutics Corp. Years of steadfast work by the Stem Cell Therapeutics scientists, staff and agents continues to build a valuable, world class patent portfolio. We are particularly excited by the first patent issued. This patent protects the newly discovered potential use of hCG for post heart attack recovery, and permits the development of new therapies in a large therapeutic market."